FDA reviewers question IDegLira's superiority to Tresiba

In Novo Nordisk A/S (CSE:NVO; NYSE:NVO) had shown its Type II diabetes combination therapy IDegLira insulin degludec/liraglutide is superior to Tresiba insulin degludec alone. The agency's FDA's Endocrinologic and Metabolic Drugs Advisory Committee is to discuss an NDA for IDegLira, which Novo markets in Europe as Xultophy.

IDegLira is a fixed-ratio combination of long-acting insulin analog Tresiba and long-acting glucagon-like peptide-1 (GLP-1) analog Victoza liraglutide. Novo markets both individually for Type II diabetes. As standalone products, Tresiba is titratable based on a patient's glycemic levels, while Victoza is a fixed-dose product. ...